ProCE Banner Activity

Leveraging Established Predictive Biomarkers for Optimal Use of Frontline Targeted Therapies in NSCLC

Slideset Download
Download these slides from a live CCO Webinar for an overview of the current status of biomarkers guiding optimal use of frontline targeted therapy in the treatment of advanced NSCLC.

Released: April 14, 2021

Expiration: April 13, 2022

No longer available for credit.

Share

Faculty

Nathan Pennell

Nathan Pennell, MD, PhD

Professor
Director,
Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Lilly

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Nathan Pennell, MD, PhD

Professor
Director,
Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Download these slides for an overview of the current status of biomarkers guiding optimal use of frontline targeted therapy in the treatment of advanced NSCLC, from CCO